Nexium Capsules Clinical Experience Investigation

The purpose of this study is to confirm the safety profile / factors which impact safety and efficacy of Nexium capsules in daily clinical usage for the patients who have been prescribed Nexium for "gastric ulcer", "duodenal ulcer", "anastomotic ulcer", "reflux oesophagitis", "non-erosive reflux disease", or "Zollinger-Ellison syndrome"

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Gastric Ulcer, Duodenal Ulcer, Anastomotic Ulcer, Reflux Oesophagitis,"Non-erosive Reflux Disease, Zollinger-Ellison Syndrome Deglutition Disorders Digestive System Diseases Digestive System Neoplasms Duodenal Diseases Duodenal Ulcer Esophageal Diseases Esophageal Motility Disorders Esophagitis Esophagitis, Peptic Gastroenteritis Gastroesophageal Reflux Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Neoplasms Non-Erosive Reflux Disease Paraneoplastic Endocrine Syndromes Paraneoplastic Syndromes Peptic Ulcer Stomach Diseases Stomach Ulcer Zollinger-Ellison Syndrome

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site, Aichi, Japan

About this study

Nexium capsules Clinical Experience Investigation

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

- Patients treated with Nexium for the first time due to gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux oesophagitis, non-erosive reflux disease, Zollinger-Ellison syndrome. Exclusion Criteria: - None

Treatment and study plan

Primary outcomes

Number of Adverse Drug Reactions

Time frame: Patients with gastric ulcer, anastomotic ulcer or Zollinger-Ellison syndrome: 8 weeks
Number of Adverse Drug Reactions

Time frame: Patients with duodenal ulcer: 6 weeks
Number of Adverse Drug Reactions

Time frame: Patients with reflux oesophagitis: 8 weeks
Number of Adverse Drug Reactions

Time frame: Patients with non-erosive reflux disease: 4 weeks

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Important dates

Study start: 2011
Primary completion: 2014
Study completion: 2014
First posted: Sep 15, 2011
Registry last updated: Apr 16, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed